Skip to main content

Table 3 Test performance inputs of cytology and Cobas® HPV test (pooled and 16/18 genotyping)

From: Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies

Input Value Source
Cytology (threshold ASCUS)
 Sensitivity CIN2 52.6% Castle et al. (2011) [28]
 Sensitivity CIN3 52.8% Castle et al. (2011) [28]
 Sensitivity CxCa 52.8% assumed to be equivalent to CIN3
 Specificity CIN2+ 76.1% Castle et al. (2011) [28]
Cytology (threshold LSIL)
 Sensitivity CIN2 39.2% Castle et al. (2011) [28]
 Sensitivity CIN3 40.1% Castle et al. (2011) [28]
 Sensitivity CxCa 40.1% assumed to be equivalent to CIN3
 Specificity CIN2 86.5% Castle et al. (2011) [28]
Cytology (threshold HSIL)
 Sensitivity CIN2 20.3% Castle et al. (2011) [28]
 Sensitivity CIN3 26.2% Castle et al. (2011) [28]
 Sensitivity CxCa 26.2% assumed to be equivalent to CIN3
 Specificity CIN2 98.3% Castle et al. (2011) [28]
Cobas® HPV test (pooled)
 Sensitivity CIN2 88.2% Castle et al. (2011) [28]
 Sensitivity CIN3 92.0% Castle et al. (2011) [28]
 Sensitivity CxCa 92.0% assumed to be equivalent to CIN3
 Specificity CIN2 57.8% Castle et al. (2011) [28]
Cobas® HPV test with genotyping 16/18
 Sensitivity 16/18 CIN2 51.8% Castle et al. (2011) [28]
 Sensitivity 16/18 CIN3 59.5% Castle et al. (2011) [28]
 Sensitivity 16/18 CxCa 65.3% Castle et al. (2011) [28]
 Specificity CIN2 75.3% Castle et al. (2011) [28]